LifeArc awards £3 million to advance promising early rare disease research from the lab to the patient
Pump-prime funding to help researchers get innovative approaches off the ground
LifeArc Ventures invests in Maxion Therapeutics
Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases
Celebrating the International Day of Women and Girls in Science
LifeArc celebrates this year's UN Day for Women and Girls in STEM.
LifeArc Ventures – strong performance in 2022 & sustained investment in innovation
LifeArc Ventures, which is committed to investing in innovative early-stage life science companies, provides an update on its portfolio.
£1 million awarded to develop cutting-edge therapies for motor neuron disease
LifeArc, Motor Neurone Disease Association and My Name’5 Doddie Foundation jointly award £1 million to progress development…
LifeArc portfolio company RQ Bio’s antibody enters clinical trials
The first of RQ Bio's discovered monoclonal antibodies to prevent COVID-19 in vulnerable patients has entered clinical trials.
Alzheimer’s drug lecanemab approved by US regulator
LifeArc’s Chief Scientific Officer Dr Dave Powell comments on news that lecanemab has received regulatory and safety approval from the FDA.
Evolving our science to solve complex healthcare challenges
Dave Powell on why LifeArc is evolving the way we do our science – and the difference we hope it will make to people’s lives.
2022 wrapped – our highlights from a pivotal year
We’ve seen some exciting scientific progress, forged new partnerships and launched some new landmark initiatives.